NGM Biopharmaceuticals
Pre-Approval PRO BETASlowing Activity
No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/25/2025
Pipeline by Phase
Therapeutic Focus
Clinical Trials (25)
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
Started: 6/25/2025
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Started: 11/14/2023
Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)
Started: 7/31/2015
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
Started: 5/16/2019
A Study of NGM621 in Participants With Geographic Atrophy
Started: 7/22/2020
A Study of NGM282 in Patients With Primary Sclerosing Cholangitis
Started: 3/1/2016
A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.
Started: 10/21/2024
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
Started: 3/23/2020
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Started: 2/1/2014
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
Started: 5/1/2014
Phase 2 Study of NGM282 in Patients With Type 2 Diabetes
Started: 9/1/2013
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Started: 10/16/2019
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Started: 3/31/2022
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Started: 6/9/2021
A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
Started: 11/9/2020
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
Started: 4/13/2021
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
Started: 4/1/2021
Study of NGM621 in Participants With Geographic Atrophy
Started: 7/26/2019
Study of Aldafermin (NGM282) in Participants With Impaired Renal Function
Started: 11/8/2019
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
Started: 1/29/2018
Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals
Started: 12/1/2015
Phase 1 Study of NGM313 in Healthy Adult Participants
Started: 2/1/2016
Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants
Started: 1/1/2013